Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related Macular Degeneration (TargetAMD) - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Human gene therapy. Clinical development Année : 2015

Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related Macular Degeneration (TargetAMD)

Dates et versions

hal-03292699 , version 1 (20-07-2021)

Identifiants

Citer

Gabriele Thumann, Maria Perdikomati-Dahmen, Zsuzsanna Izsvak, Zoltan Ivics, Alfredo Garcia Layana, et al.. Transposon-Based, Targeted Ex Vivo Gene Therapy to Treat Age-Related Macular Degeneration (TargetAMD). Human gene therapy. Clinical development, 2015, 26 (2), pp.97-100. ⟨10.1089/humc.2015.2519⟩. ⟨hal-03292699⟩
17 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More